Actively Recruiting
Phase 12 Study Evaluating Rina-S in Locally Advanced and Metastatic Solid Tumors Including Ovarian, Breast, Lung, and Endometrial Cancers
Led by Genmab · Updated on 2026-11-04
952
Participants Needed
67
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying Rina-S, a targeted antibody-drug conjugate aimed at treating participants with solid tumors that are either metastatic or cannot be removed by surgery. This Phase 12 trial evaluates Rina-Ss safety, side effects, how the body processes the drug, and its potential anti-tumor effects across various cancers including ovarian, endometrial, breast, lung, and mesothelioma. Participants receive Rina-S either alone or in combination with other cancer drugs like carboplatin, bevacizumab, pembrolizumab, or CYP3A4 inhibitors such as erythromycin or itraconazole. The study includes multiple parts, each focusing on different tumor types or combinations of therapies. Treatment continues until disease progression, unacceptable side effects, withdrawal of consent, or other specified reasons. During the study, participants undergo regular evaluations including monitoring for side effects, tumor response assessments using imaging criteria, and blood tests to measure drug levels and antibodies. Safety and effectiveness data are collected for up to about one year, with some outcomes followed for up to two years. Participants remain under medical supervision throughout the trial duration, which runs until March 2029.
CONDITIONS
Brief Title
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Research Team
G
Genmab Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here